Abstract:Anaplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer demonstrates remarkable sensitivity to crizotinib.1Camidge DR Bang YJ Kwak EL et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012; 13: 1011-1019Abstract Full Text Full Text PDF PubMed Scopus (1064) Google Scholar Although other methods exist, the dominant method for determining ALK positivity uses the Abbott (Abbott Molecular, Des Plaines, IL) ALK break-apart fluorescent in situ hybridization (FISH) assay.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar The assay has clearly defined positivity criteria but borderline or atypical negative cases occur. Here we describe a case with an atypical negative FISH result that was later confirmed as ALK+ by both immunohistochemistry (IHC) and reverse transcription polymerase chain reaction (RT-PCR)and responded well to crizotinib. A 44-year-old Chinese man with a 7 pack-year smoking history was referred to Shanghai Pulmonary Hospital in February 2013 for a left upper lobe lung mass with multiple bilateral intrapulmonary metastases, left pleural effusion, and 2R/4R/10L/11L lymphadenopathy. Pleural fluid cytology revealed adenocarcinoma and Scorpion Amplification Refractory Mutation system (AmoyDx Co., Xiamen, China). showed no detectable epidermal growth factor receptor mutation. He commenced chemotherapy with gemcitabine and cisplatin. However, after a single cycle, his symptoms worsened and imaging confirmed progressive disease. A second opinion was requested from the University of Colorado and a computed tomography–guided biopsy of the left upper lobe lesion was performed to permit additional molecular testing. In the interim, the patient commenced pemetrexed and nedaplatin. Unfortunately, after two cycles his shortness of breath worsened, with evidence of further progression on his scans (Fig. 1A). Molecular testing on his repeat biopsy specimen revealed no mutations by SNaPshot multiplex PCR testing (Life Technologies, Carlsbad, CA). However, although technically negative, the ALK break-apart FISH test showed an atypical negative pattern. Specifically, 68% of cells demonstrated single copies of the 5′ ALK signal and numerous cells with doublets of the 5′ ALK signal combined with one 3′ ALK signal (Fig. 2A). Subsequently, confirmatory diagnostic assays demonstrated ALK protein expression by IHC using the D5F3 antibody (Cell Signaling Technology Inc., Danvers, MA; H score = 150; Fig. 2B) and the presence of an echinoderm microtubule-associated protein-like 4 (EML4)-ALK transcript (E13;A20) by RT-PCR (Fig. 2C). The patient then received crizotinib (250 mg twice daily) as third-line therapy in May 2013 with an impressive symptomatic improvement and CT response after 1 month of therapy (Fig. 1B). He remains on treatment with crizotinib with no evidence of progression as of September 2013. Isolated 5′ ALK signals have previously been reported, although, because the 5′ probe is not located in the kinase region of ALK, these are usually considered ALK negative by FISH.3Yoshida A Tsuta K Nitta H et al.Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.J Thorac Oncol. 2011; 6: 1677-1686Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar,4Camidge DR Kono SA Flacco A et al.Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.Clin Cancer Res. 2010; 16: 5581-5590Crossref PubMed Scopus (297) Google Scholar Our patient showed multiple single copies of the 5′ ALK signal plus additional 5′ doublets combined with 3′ signals, suggesting the possibility of a complex rearrangement. ALK positivity was confirmed by both IHC and RT-PCR and the patient responded well to crizotinib. A complex rearrangement generating a different atypical negative FISH pattern (3′ doublets fused with 5′ signals) that also harbored a functional ALK fusion was recently described.5Peled N Palmer G Hirsch FR et al.Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.J Thorac Oncol. 2012; 7: e14-e16Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar When FISH is the initial diagnostic assay, consideration should be given to formally defining an atypical negative ALK FISH category for additional interrogation with alternative confirmatory assays.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer

Anaplastic Lymphoma Kinase Variants and the Percentage of Alk-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced Nsclc

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib Versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

Investigation on the Prognostic Impact of Concurrent Genomic Alterations in Crizotinib-Treated EML4-ALK-rearranged Advanced Non-Small Cell Lung Cancer Patients.

Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer

Comparison of ALK Detection by FISH, IHC and NGS to Predict Benefit from Crizotinib in Advanced Non-Small-cell Lung Cancer.

The Correlation Between Crizotinib Efficacy and Molecular Heterogeneity by Next-Generation Sequencing in Non-Small Cell Lung Cancer.

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Versus Chemotherapy As a First-Line Treatment

MA26.05 Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants

A Survival Comparison Study of Chinese Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements with Crizotinib Treatment Detected by FISH, IHC, and RT-PCR.

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

P1.01-006 Effect of EML-Alk Fusion Variant and Fusion Abundance on the Efficacy of Crizotinib in Non-Small Cell Lung Cancer

Clinical Characteristics of ALK+ NSCLC Patients (pts) Treated with Crizotinib Beyond Disease Progression (PD): Potential Implications for Management.

Atypical Negative Alk Break-Apart Fish Harboring A Crizotinib-Responsive Alk Rearrangement in Non-Small-Cell Lung Cancer

Alectinib Versus Crizotinib in Untreated Asian Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer (ALESIA): a Randomised Phase 3 Study.

P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers